US5565462A - Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative - Google Patents

Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative Download PDF

Info

Publication number
US5565462A
US5565462A US08/263,399 US26339994A US5565462A US 5565462 A US5565462 A US 5565462A US 26339994 A US26339994 A US 26339994A US 5565462 A US5565462 A US 5565462A
Authority
US
United States
Prior art keywords
treatment
psoriasis
pentoxifylline
atopic dermatitis
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/263,399
Other languages
English (en)
Inventor
Anat Eitan
Rachel Nachman
Sasson Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Ramot at Tel Aviv University Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Ramot at Tel Aviv University Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to US08/263,399 priority Critical patent/US5565462A/en
Application granted granted Critical
Publication of US5565462A publication Critical patent/US5565462A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • This invention relates to topical pharmaceutical compositions for and a method of treating inflammatory and proliferative skin diseases such as psoriasis and atopic dermatitis.
  • Psoriasis is a common chronic relapsing inflammatory skin disease which affects 1-3% of the population. It is characterised by the circumscribed scaling erythematous plaques of various sizes and forms which in some cases may extend to more than 50% of the skin area.
  • the psoriatic condition is composed of two main processes: cellular hyperproliferation and inflammation. Despite extensive research the etiology of the disease is still unknown.
  • Psoriasis is currently treated by a number of methods which include topical applications consisting of tar derivatives, steroids, vitamin D and its derivatives or vitamin A and its derivatives (J. P. Callen, Drug Therapy, April 1987, pp. 29-35). These therapies are only partially successful and may be accompanied by undesired side affects. Thus although steroids can be very effective, they are also frequently associated with side effects. Other therapies include phototherapy with or without concomitant systemic administration of psoralen derivatives. Additionally, systemic administration of steroids, methotrexate and cyclosporine have been used for treatment of severe cases of psoriasis. All of these therapies are associated with side effects. There is thus an urgent need for new effective, non-toxic therapeutics for psoriasis.
  • Atopic dermatitis is a chronic skin condition of unknown etiology, and which may be continuous from infancy to adulthood. There is about 4% incidence of atopic dermatitis from birth to 7 years (Halpern et al., J. Allergy Clin. Immunol. 51:139-151 (1973). In childhood, it is characterized by papules, erythema, thickening and lichenification. In the adolescent, the main symptoms are thickening and lichenification with erythema and scaling. Pruritis is a general feature of the disease. Systemic therapy includes antihistamine drugs and steroids, but the latter are reserved for unmanageable cases and used for the shortest period possible. Topical therapy includes fluorinated and fluorochlorinated corticosteroid preparations, but striae and cataracts are likely complications. Clearly there is as yet no satisfactory and safe drug treatment for atopic dermatitis.
  • Xanthine derivatives have been proposed for the treatment of psoriasis and atopic dermatitis.
  • U.S. Pat. No. 4,141,976 proposes certain pharmaceutical preparations for the topical treatment of psoriasis.
  • the compounds described are certain substituted alkylxanthine derivatives and substituted thioxanthines.
  • RO 20-1724 d,1-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone, which is not a xanthine derivative.
  • RO 20-1724 d,1-4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
  • WO 9101730 describes the use of certain xanthine derivatives for the treatment of asthma, urticaria, eczema and rhinitis. Suggested modes of administration are listed as oral, rectal, topical, parenteral, intravenous, or intramuscular or through the respiratory tract.
  • EP 195,496 describes the use of certain xanthine derivatives for treating proliferative skin disease such as psoriasis. The xanthine derivatives are administered orally.
  • U.S. Pat. No. 4,716,165 describes the use of certain theobromine derivatives for treating asthma, allergic rhinitis, atopic dermatitis or eczema.
  • WO 8905145 describes the use of certain xanthine derivatives for the treatment of a wide variety of disease states including psoriasis.
  • EP 260,127 describes the oral administration of certain xanthine derivatives for the treatment of proliferative skin disease.
  • U.S. 4,341,783 describes the use of topical dyphylline for the treatment of psoriasis.
  • Pentoxifylline (3,7-dimethyl-1-(5-oxohexyl)-xanthine), propentofylline (PPF) (3-methyl-7-propyl-1-(5-oxohexyl)-xanthine) and torbafylline (TBF) (3-methyl-7-ethoxymethyl-1-(5-hydroxy-5-methylhexyl)-xanthine are related methyl-xanthine derivatives which are well known in the art for treatment of a variety of disease states.
  • PTX is widely used systemically for the treatment of peripheral vascular diseases.
  • PTX and PPF have been administered systemically for the treatment of senile dementia while systemic administration of TBF is under investigation for treatment of senile dementia, peripheral vascular disease and myopathy.
  • PTX has been used systemically for the treatment of various cutaneous lesions associated with or due to impaired or deficient blood flow in the dermis layer of skin and its effectiveness in the treatment of peripheral vascular diseases is described by H. Ely, Dermatologic Clinics 6:585-608 (1988). There is no teaching that PTX, or any of its congeners, PPF or TBF, were effective in the treatment of psoriasis or atopic dermatitis, which are lesions of the epidermis layer of the skin rather than one of the peripheral blood vessels.
  • a pharmaceutical composition comprising a compound selected from the group of pentoxifylline, propentofylline and torbafylline dramatically improves the psoriatic lesions of patients.
  • the improvement is greater than that achieved with other xanthine derivatives such as dyphylline which are taught in the prior art as useful for the topical treatment of psoriatic lesions.
  • the present invention provides a pharmaceutical composition for the topical treatment of psoriasis or atopic dermatitis comprising an effective amount of an active compound selected from the group of pentoxifylline, propentofylline and torbafylline, and a pharmaceutically acceptable carrier.
  • the concentration of the active compound is about 0.5%-5% (w/w).
  • the active compound is pentoxifylline its concentration is preferably 2% (w/w).
  • compositions according to the invention may additionally contain therapeutically effective amounts of one or more compound which are known to be of use in the topical treatment of psoriasis and atopic dermatitis.
  • compounds are well known to those skilled in the art and include cyclosporine, methotrexate, tamoxifen, forskolin and analogs, tar derivatives, steroids, vitamin A and its derivatives vitamin D and its derivatives including 1-alpha-hydroxy-cholecalciferol, 1,25-dihydroxy-cholecalciferol, 24,25-dihydroxy-cholecalciferol, 1,24-dihydroxy-cholecalciferol and calcipotriol (MC 903), and beta agonists such as terbutaline.
  • compositions according to the invention may contain one or more of the compounds adenosine and related purines, lipoxygenase inhibitors, substance P antagonists, delta tocopherol, 2-heptanone, and fatty acids and their esters such as heptanoic acid, ethyl heptanoate, 3,3-dimethylbutyric acid, and lipoic acid.
  • the pharmaceutically acceptable carrier of the compositions according to the invention may contain any of the components which are used in topical compositions and are well known to those skilled in the art.
  • the pharmaceutically acceptable carrier of the compositions according to the invention may also contain penetration enhancers such as urea, lactic acid, ammonium lactate, salicylic acid or a C 3 -C 12 -straight chain alkanoic acid.
  • penetration enhancers such as urea, lactic acid, ammonium lactate, salicylic acid or a C 3 -C 12 -straight chain alkanoic acid.
  • compositions may be in the form of lotions, creams, ointments and gels, and also in the form of sprayable aerosols.
  • Preferred formulations of the compositions according to the invention are creams, which may further contain saturated or unsaturated fatty acids such as stearic acid, palmitic acid, oleic acid, palmito-oleic acid, cetyl or oleyl alcohols, stearic acid being particularly preferred.
  • Creams of the invention may also contain a non-ionic surfactant, typically polyoxy-40-stearate.
  • the invention also provides a method for the treatment of a subject suffering from psoriasis or atopic dermatitis comprising topically applying to the subject a therapeutically effective amount of an active compound selected from the group consisting of pentoxifylline, propentofylline and torbafylline if desired together with a pharmaceutically acceptable carrier.
  • the preferred active compound for the performance of the method according to the invention is pentoxifylline.
  • the said active compound may be applied together with a therapeutically effective amount of one or more additional compounds which are known to be of use in the topical treatment of psoriasis and atopic dermatitis.
  • additional compounds which are known to be of use in the topical treatment of psoriasis and atopic dermatitis.
  • These compounds are well known to those skilled in the art and include cyclosporine, methotrexate, tamoxifen, forskolin and analogs thereof, tar derivatives, steroids, vitamin A and its derivatives, or vitamin D and its derivatives including 1-alpha-hydroxy-cholecalciferol, 1,25-dihydroxy-cholecalciferol24,25-dihydroxy-cholecalciferol,1,24-dihydroxy-cholecalciferol and calcipotriol (MC 903), and beta agonists such as terbutaline.
  • the said active substance may be applied together with an effective amount of at least one member of the group of adenosine and related purines, lipooxygenase inhibitors, substance P antagonists, delta tocopherol, 2-heptanone, and fatty acids and their esters such as heptanoic acid, ethyl heptanoate, 3,3-dimethylbutyric acid, and lipoic acid.
  • the invention provides for use of a compound selected from the group consisting of pentoxifylline, propentofylline and torbafylline for the preparation of pharmaceutical compositions for the topical treatment of human patients suffering from psoriasis of atopic dermatitis.
  • Example 1 the advantages achieved in accordance with the invention are described, i.a. with reference to the annexed pictures in which:
  • FIG. 1 shows photomicrographs of transverse sections of human psoriatic skin transplants before and after treatment
  • FIG. 2 shows two further similar photomicrographs.
  • Pentoxifylline was formulated into a cream for topical application as follows:
  • Pentoxifylline was formulated into an ointment for topical application as follows:
  • Pentoxifylline was formulated into a gel suitable for topical application as follows:
  • the severity of the psoriatic lesion was evaluated and the PASI index was calculated as described by Fredrikson and Petterson (Dermatologica 157:238-244 (1978)).
  • the area (A) of the psoriasis in four main body parts (head (H), trunk (T), upper extremities (U) and lower extremities (L)) is assigned a value from 0-6 depending on the extent of psoriasis where O reflects no involvement and 6 reflects 90-100% involvement.
  • the severity of the lesion is assessed based on three parameters: Erythema (E), Desquamation (scaling) (D) and Infiltration (I). The severity of each of these parameters is measured on a scale of 0-4 where 0 is no involvement and 4 is very sever.
  • the total severity score is calculated according to the following formula:
  • split thickness biopsies of nonpustular psoriatic human tissue, 4 ⁇ 5 cm and 0.4 mm thick were obtained from the edge of established plaques from various donor patients. Each specimen was divided into sections as follows: 4-5 sections, 2 ⁇ 2 mm each for thymidine incorporation and subsequent autoradiography in order to assess the rate of proliferation in the epidermis; 1-2 sections 0.5 ⁇ 1 cm each for histological examination prior to grafting in order to evaluate the severity of the disease, as quantitated by the measure of epidermal thickness; and 3 sections 1.5 ⁇ 1 cm each for grafting on the dorsal side of each of three different nude mice. The grafts were allowed to heal for one week prior to topical application of the test preparations.
  • mice Outbred Balb/C nude mice, 2 to 3 months of age were used in this study.
  • the mice were obtained from the pathogen free animal breeding facility at the University of Tel Aviv (Israel) and were raised in the pathogen-free animal facility at the Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • the graft area was treated daily with the test drug in a cream composition according to Example 1 or vehicle alone by applying 200 ⁇ l of the preparation, once at 08:00 and once at 21:00 for the duration of 7 days.
  • Table 1 shows the effect of the topical preparations tested on human psoriatic skin transplanted in nude mice according to the procedure outlined above.
  • the results of the experiment shown in Table 1 demonstrate that pentoxifylline is almost as effective as steroids in treating psoriasis and far more effective than dyphylline, a related xanthine which was shown to be virtually inactive.
  • Table 2 shows the results of the application of topical skin formulations to transplanted human psoriatic skin in each of the 28 nude mice. The results are expressed as a success ratio where success is defined as a decrease of at least 15% in epidermal thickness (acanthosis) as a result of the 7 day topical treatment. The treatments were applied as creams and were administered as described above.
  • Panel A shows a transplant before treatment and panels B and C show transplants after daily treatments for seven days with the 2% PTX cream of Example 1 and an 0.05% clobetasol propionate ointment, respectively.
  • FIG. 2 shows similar photomicrographs before and after daily treatment for seven days with 8% dyphylline.
  • atopic dermatitis is transferable by bone marrow cells indicating that primary site of disease is in the immune and inflammatory cells which infiltrate the skin.
  • lymphocytes are thought to be one of the targets for treatment of the disease.
  • various cells (including lymphocytes) and organs derived from atopic subjects showed a common impaired response to cAMP agonists.
  • atopic lymphocytes behavior in response to various agents is predictive of the atopic individuals response to these agents.
  • cAMP agonists have an inhibitory effect on the mitogenic stimulation of peripheral blood mononuclear cells (PBMC) from atopic subjects (Ravid et al., J. Allergy Clin. Immunol. 86:881-885 (1990)).
  • PBMC peripheral blood mononuclear cells
  • steroids such as dexamethasone, which are used in the treatment of atopic dermatitis, inhibited the mitogenic stimulation of PBMC.
  • the inhibitory effect of certain compounds on the mitogenic stimulation of PBMC isolated from healthy and atopic individuals is predictive of the effect of these compounds in the treatment of atopic diseases, including atopic dermatitis.
  • PBM cells peripheral blood mononuclear cells
  • PBM cells were separated by Ficoll-Hypaque density gradient centrifugation. Partial depletion of adherent cells was achieved by incubating PBM cells for 90 min in plastic petri dishes at 37° C. at a concentration of 5 ⁇ 10 4 cells/mL in RPMI-1640 medium containing 2% heat-inactivated newborn calf serum. The nonadhering cells were stirred gently and carefully collected. The monocyte content of PBM cells was thus reduced to 3-7%.
  • PBM cells were suspended (1 ⁇ 10 4 /mL) in RPMI-1640 medium containing 5% heat-inactivated pooled human AB serum supplemented with penicillin (100 U/mL) and streptomycin (100 ⁇ g/mL). Cells were incubated at 37° C. in a humidified 5% CO 2 -95% air atmosphere in 0.2 mL aliquots in 96-well flat bottomed Cooke microtiter plates. PHA (1 ⁇ g/mL), indomethacin (5 ⁇ g/mL) and various xanthine derivatives were added at initiation of culture. Indomethacin was dissolved in ethanol.
  • a clinical trial was performed comparing a cream composition of 2% pentoxifylline (formulation A of Example 1) to placebo.
  • the trial was randomized, double blind, placebo controlled, right-left comparison within patient design.
  • Two similar plaque areas of psoriasis i.e. both legs or forearms
  • pentoxifylline formulated as in Example 1
  • placebo cream formulated identically but without the pentoxifylline.
  • the cream (formulation A in Example 1) was applied by the patient twice daily.
  • Psoriasis Area Severity Index was calculated for each of the 2 lesions on each patient as follows:
  • Patient 1 After 1.5 weeks of treatment the patient showed a 58% decrease in PASI on the pentoxifylline treated side and 0% decrease in PASI on the placebo treated side.
  • Patient 2 After 2 weeks of treatment the patient showed a 53% decrease in PASI on the pentoxifylline treated side and 34% decrease in PASI on the placebo treated side.
  • Patient 3 After 2 weeks of treatment the patient showed a 73% decrease in PASI on the pentoxifylline treated side and 45% decrease in PASI on the placebo treated side. After 6 weeks of treatment the decrease in PASI on the pentoxifylline treated side was 90% and on the placebo treated side 56%.
  • Patient 4 After 6 weeks of treatment the patient showed a 91% decrease in PASI on the pentoxifylline treated side and 73% decrease in PASI on the placebo treated side. After 8 weeks of treatment the decrease in PASI on the pentoxifylline treated side was 88% and on the placebo treated side 57%.
  • Patient 5 After 2 weeks of treatment the patient showed a 73% decrease in PASI on the pentoxifylline treated side and 25% decrease in PASI on the placebo treated side.
  • Pentoxifylline cream or the placebo (the identical cream, but without the pentoxifylline) were dispensed in identical tubes that were marked for application to right and left sides. Patients were instructed to apply medication twice a day (morning and evening) for four weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US08/263,399 1991-09-02 1994-06-21 Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative Expired - Fee Related US5565462A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/263,399 US5565462A (en) 1991-09-02 1994-06-21 Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL9936891A IL99368A (en) 1991-09-02 1991-09-02 Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
IL99368 1991-09-02
US93426892A 1992-08-25 1992-08-25
US08/263,399 US5565462A (en) 1991-09-02 1994-06-21 Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US93426892A Continuation 1991-09-02 1992-08-25

Publications (1)

Publication Number Publication Date
US5565462A true US5565462A (en) 1996-10-15

Family

ID=11062864

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/263,399 Expired - Fee Related US5565462A (en) 1991-09-02 1994-06-21 Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative

Country Status (7)

Country Link
US (1) US5565462A (fr)
EP (1) EP0544391A1 (fr)
JP (1) JPH06192101A (fr)
AU (1) AU650995B2 (fr)
CA (1) CA2076699A1 (fr)
IL (1) IL99368A (fr)
ZA (1) ZA926248B (fr)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007400A1 (fr) * 1996-08-22 1998-02-26 Theratech, Inc. Compositions transdermiques a base de propentofylline pour le traitement de la maladie d'alzheimer
US5730998A (en) * 1994-12-19 1998-03-24 Societe L'oreal S.A. Use of a substance P antagonist for the treatment of pruritus, ocular and/or palpebral pain and ocular or palpebral dysaesthesia
US5744156A (en) * 1994-12-19 1998-04-28 Societe L'oreal S.A. Use of a substance P antagonist for the treatment of skin reddening of neurogenic origin
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
DE10111040A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
WO2002096429A1 (fr) * 2001-05-29 2002-12-05 Muratov, Igor Aleksandrovich Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant
WO2003007938A1 (fr) * 2001-07-17 2003-01-30 Aidan, Inc. Procede de traitement de la dermatite atopique
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US20030186926A1 (en) * 2001-10-01 2003-10-02 Linden Joel M. 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US20050181028A1 (en) * 2003-01-23 2005-08-18 Foote Mary A. Topical composition and method for treating occlusive wounds
US20050182018A1 (en) * 1999-02-01 2005-08-18 Linden Joel M. Method to reduce inflammatory response in transplanted tissue
US20060040888A1 (en) * 2004-08-02 2006-02-23 Rieger Jayson M 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity
US20060040889A1 (en) * 2004-08-02 2006-02-23 Rieger Jayson M 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US20060100169A1 (en) * 1999-02-01 2006-05-11 Rieger Jayson M Method to reduce an inflammatory response from arthritis
US20060217343A1 (en) * 2004-08-02 2006-09-28 Rieger Jayson M 2-Polycyclic propynyl adenosine analogs having A2A agonist activity
FR2884419A1 (fr) * 2005-04-19 2006-10-20 Galderma Sa Composition de type solution filmogene comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
WO2006111426A1 (fr) * 2005-04-19 2006-10-26 Galderma S.A. Composition d'une solution de type filmogene, comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
BG65115B1 (bg) * 1999-04-23 2007-03-30 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Фармацевтичен състав
US20080009460A1 (en) * 2006-02-10 2008-01-10 Linden Joel M Method to treat sickle cell disease
US20080064669A1 (en) * 2006-08-29 2008-03-13 Rakefet Cohen Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility
US20080064653A1 (en) * 2006-06-19 2008-03-13 University Of Virginia Patent Foundation Use of adenosine a2a modulators to treat spinal cord injury
US20090042901A1 (en) * 2005-02-02 2009-02-12 Kowa Co., Ltd. Agent for prevention/therapy of disease caused by keratinocyte growth
US20090162282A1 (en) * 2007-12-20 2009-06-25 Robert Douglas Thompson Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists
US20110129546A1 (en) * 2008-06-20 2011-06-02 Ignacio Umbert Mill Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same
US20110159077A1 (en) * 2008-09-12 2011-06-30 Patricio Roberto Figueroa Lizama Pentoxifilin-based dermatological pharmaceutical composition, for topical application, in cream, gel, solution, emulsion, liposome and microcapsule form
US10772813B2 (en) 2016-06-03 2020-09-15 Colradel, LLC Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
FR2740040B1 (fr) * 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO2002045718A1 (fr) * 2000-12-08 2002-06-13 Institut Pasteur De Lille Utilisation de composes actifs capables de moduler la voie intracellulaire declenchee par le recepteur de dp dans des cellules de langerhans
AU2001243556A1 (en) * 2001-03-12 2002-09-24 Alydar Pharmaceuticals, Inc. Screening non-peptide, non-steroid invertebrate pheromone compounds for mitogen-activated protein kinase modulating activity
WO2004069247A1 (fr) * 2003-02-06 2004-08-19 Cipla Ltd Immunotherapie topique et compositions destinees a etre utilisees pour celle-ci
GB0401398D0 (en) * 2004-01-22 2004-02-25 Arachnova Therapeutics Ltd New theraputic use
RU2496476C1 (ru) * 2012-08-10 2013-10-27 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "УрНИИДВиИ" Минздравсоцразвития России) Средство наружной терапии для больных атопическим дерматитом
CN108949214A (zh) * 2018-08-08 2018-12-07 唐山市新雅诺生物科技有限公司 一种一次蒸馏木醋液、精制木焦油、用于杀除和抑制皮癣菌类的膏剂及其制备方法
WO2022042390A1 (fr) * 2020-08-25 2022-03-03 广东众生睿创生物科技有限公司 Utilisation de composés d'hydroxypurine pour le traitement de maladies de la peau

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141976A (en) * 1976-01-05 1979-02-27 The Regents Of The University Of Michigan Process for alleviating proliferative skin diseases
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
US4369181A (en) * 1981-08-05 1983-01-18 Sri International Process for treating proliferative skin diseases using certain 6,8-substituted ribofuranosylpurine-3',5'-cyclic phosphates
EP0158090A1 (fr) * 1984-03-07 1985-10-16 Roshdy Dr. Ismail Médicament pour le traitement et la protection de la peau
US4594432A (en) * 1983-01-28 1986-06-10 Hoffman-La Roche Inc. Process for the synthesis of 1α,23(S),25-trihydroxycholecalciferol and 1α,23(R),25-trihydroxycholecalciferol
US4612308A (en) * 1984-11-29 1986-09-16 Hoffmann-La Roche Inc. 25,26-Dehydro-1α,23(S,R)-dihydroxycholecalciferol and its epimers
EP0195496A2 (fr) * 1985-01-21 1986-09-24 Beecham Group Plc Utilisation de xanthines dans le traitement de l'affection proliférative de la peau
US4617279A (en) * 1984-09-14 1986-10-14 Asahi Glass Company Ltd. Calcium phosphate type crystallizable glass
US4711881A (en) * 1984-08-10 1987-12-08 Taisho Pharmaceutical Co., Ltd. 1α,25-dihydroxy-26,27-dimethylcholecalciferol and its use in the treatment of calcium pathobolism
US4716165A (en) * 1986-09-24 1987-12-29 American Home Products Corporation Histamine H1 antagonists
US4719205A (en) * 1984-01-30 1988-01-12 Wisconsin Alumini Research Foundation Side-chain unsaturated 1-hydroxyvitamin D compounds
EP0260127A2 (fr) * 1986-09-11 1988-03-16 BEECHAM - WUELFING GmbH & Co. KG Dérivés de xanthine, leur préparation et compositions pharmaceutiques les contenant
US4804502A (en) * 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
US4832875A (en) * 1985-11-21 1989-05-23 Taisho Pharmaceutical Co., Ltd. Vitamin D3 derivative
WO1989005145A1 (fr) * 1987-12-11 1989-06-15 Hoechst-Roussel Pharmaceuticals Incorporated Procede d'inhibition de l'activite de citokines derivees de leukocytes
US4851401A (en) * 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
US4868165A (en) * 1985-05-30 1989-09-19 Taisho Pharmaceutical Co., Ltd. 24,24-difluoro-26,27-dimethylvitamin D3 derivatives
USRE33107E (en) * 1983-03-22 1989-11-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
WO1991001730A2 (fr) * 1989-08-10 1991-02-21 Beecham Group Plc Utilisation de derives de xanthine comme inhibiteurs de l'eosinophilia du sang induit
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5190935A (en) * 1989-07-10 1993-03-02 Leo Pharmaceutical Products Ltd. Vitamin d analogues
US5194431A (en) * 1992-07-08 1993-03-16 Wisconsin Alumni Research Foundation 24-cyclopropane vitamin D derivatives
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5200536A (en) * 1992-02-10 1993-04-06 Daikin Industries Ltd. Fluorine-containing vitamin D3 analogues
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
US5292728A (en) * 1990-04-06 1994-03-08 Schering Aktiengesellschaft 24-Oxa derivatives in the vitamin D series

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511557A (en) * 1981-08-24 1985-04-16 Gauri Kailash Kumar Pharmaceutical composition

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141976A (en) * 1976-01-05 1979-02-27 The Regents Of The University Of Michigan Process for alleviating proliferative skin diseases
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
US4369181A (en) * 1981-08-05 1983-01-18 Sri International Process for treating proliferative skin diseases using certain 6,8-substituted ribofuranosylpurine-3',5'-cyclic phosphates
US4369181B1 (fr) * 1981-08-05 1985-07-16
US4594432A (en) * 1983-01-28 1986-06-10 Hoffman-La Roche Inc. Process for the synthesis of 1α,23(S),25-trihydroxycholecalciferol and 1α,23(R),25-trihydroxycholecalciferol
USRE33107E (en) * 1983-03-22 1989-11-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
US4719205A (en) * 1984-01-30 1988-01-12 Wisconsin Alumini Research Foundation Side-chain unsaturated 1-hydroxyvitamin D compounds
EP0158090A1 (fr) * 1984-03-07 1985-10-16 Roshdy Dr. Ismail Médicament pour le traitement et la protection de la peau
US4938960A (en) * 1984-03-07 1990-07-03 Roshdy Ismail Agents for the treatment and protection of the skin
US4711881A (en) * 1984-08-10 1987-12-08 Taisho Pharmaceutical Co., Ltd. 1α,25-dihydroxy-26,27-dimethylcholecalciferol and its use in the treatment of calcium pathobolism
US4617279A (en) * 1984-09-14 1986-10-14 Asahi Glass Company Ltd. Calcium phosphate type crystallizable glass
US4612308A (en) * 1984-11-29 1986-09-16 Hoffmann-La Roche Inc. 25,26-Dehydro-1α,23(S,R)-dihydroxycholecalciferol and its epimers
EP0195496A2 (fr) * 1985-01-21 1986-09-24 Beecham Group Plc Utilisation de xanthines dans le traitement de l'affection proliférative de la peau
US4868165A (en) * 1985-05-30 1989-09-19 Taisho Pharmaceutical Co., Ltd. 24,24-difluoro-26,27-dimethylvitamin D3 derivatives
US4832875A (en) * 1985-11-21 1989-05-23 Taisho Pharmaceutical Co., Ltd. Vitamin D3 derivative
EP0260127A2 (fr) * 1986-09-11 1988-03-16 BEECHAM - WUELFING GmbH & Co. KG Dérivés de xanthine, leur préparation et compositions pharmaceutiques les contenant
US4716165A (en) * 1986-09-24 1987-12-29 American Home Products Corporation Histamine H1 antagonists
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
WO1989005145A1 (fr) * 1987-12-11 1989-06-15 Hoechst-Roussel Pharmaceuticals Incorporated Procede d'inhibition de l'activite de citokines derivees de leukocytes
US4804502A (en) * 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
US4851401A (en) * 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
US5190935A (en) * 1989-07-10 1993-03-02 Leo Pharmaceutical Products Ltd. Vitamin d analogues
WO1991001730A2 (fr) * 1989-08-10 1991-02-21 Beecham Group Plc Utilisation de derives de xanthine comme inhibiteurs de l'eosinophilia du sang induit
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
US5292728A (en) * 1990-04-06 1994-03-08 Schering Aktiengesellschaft 24-Oxa derivatives in the vitamin D series
US5200536A (en) * 1992-02-10 1993-04-06 Daikin Industries Ltd. Fluorine-containing vitamin D3 analogues
US5194431A (en) * 1992-07-08 1993-03-16 Wisconsin Alumni Research Foundation 24-cyclopropane vitamin D derivatives

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts 107:223073e (1987). *
Dermatologic Clinics vol. 6, No. 4, Oct. 1988, pp. 585 608, Haines Ely, M.D. Pentoxifylline Therapy in Dermatology. *
Dermatologic Clinics-vol. 6, No. 4, Oct. 1988, pp. 585-608, Haines Ely, M.D. Pentoxifylline Therapy in Dermatology.
Drug Therapy, Apr. 1987, pp. 29 38, Jeffrey P. Callon, M.D. Papulosquamous Lesions. *
Drug Therapy, Apr. 1987, pp. 29-38, Jeffrey P. Callon, M.D. Papulosquamous Lesions.
J. Allergy Clin. Immunol, Dec. 1990, vol. 86, No. 6, Part 1, pp. 881 885. *
J. Allergy Clin. Immunol, Dec. 1990, vol. 86, No. 6, Part 1, pp. 881-885.
J. Allergy Clin. Immunol, Mar. 1973, vol. 51, No. 33, pp. 139 151, Halpern et al Development of childhood allergy in infants fed breast, soy, or cow milk. *
J. Allergy Clin. Immunol, Mar. 1973, vol. 51, No. 33, pp. 139-151, Halpern et al Development of childhood allergy in infants fed breast, soy, or cow milk.
Journal of Clinical Endocrinology and Metabolism, vol. 70, No. 6, pp. 168692, 1990.
Journal of Clinical Endocrinology and Metabolism, vol. 70, No. 6, pp. 1687 1692, 1990. *

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5730998A (en) * 1994-12-19 1998-03-24 Societe L'oreal S.A. Use of a substance P antagonist for the treatment of pruritus, ocular and/or palpebral pain and ocular or palpebral dysaesthesia
US5744156A (en) * 1994-12-19 1998-04-28 Societe L'oreal S.A. Use of a substance P antagonist for the treatment of skin reddening of neurogenic origin
US5762953A (en) * 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
WO1998007400A1 (fr) * 1996-08-22 1998-02-26 Theratech, Inc. Compositions transdermiques a base de propentofylline pour le traitement de la maladie d'alzheimer
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20060020020A1 (en) * 1999-01-13 2006-01-26 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20040127474A1 (en) * 1999-01-13 2004-07-01 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US6686388B2 (en) 1999-01-13 2004-02-03 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20050182018A1 (en) * 1999-02-01 2005-08-18 Linden Joel M. Method to reduce inflammatory response in transplanted tissue
US7226913B2 (en) 1999-02-01 2007-06-05 University Of Virginia Patent Foundation Pharmaceutical compositions having A2A adenosine receptor agonist activity
US6531457B2 (en) 1999-02-01 2003-03-11 University Of Virginia Methods and compositions for treating inflammatory response
US20060100169A1 (en) * 1999-02-01 2006-05-11 Rieger Jayson M Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US20070265440A1 (en) * 1999-02-01 2007-11-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
EP3146969A1 (fr) 1999-04-23 2017-03-29 Leo Pharma A/S Pommades pour le traitement topique du psoriasis
EP2455083A1 (fr) 1999-04-23 2012-05-23 Leo Pharma A/S Composition pharmaceutique pour application dermique comprenant du calcipotriol et une corticostéroïde
EP2915534A1 (fr) 1999-04-23 2015-09-09 Leo Pharma A/S Composition pharmaceutique pour le traitement dermique du psoriasis comprenant une vitamine D et une corticostéroïde
EP2450043A1 (fr) 1999-04-23 2012-05-09 Leo Pharma A/S Composition pharmaceutique pour le traitement dermique du psoriasis, du sébopsoriasis ou de la dermatite séborrhéique comprenant une vitamine D et une corticostéroïde
BG65115B1 (bg) * 1999-04-23 2007-03-30 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Фармацевтичен състав
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
DE10111040A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
WO2002096429A1 (fr) * 2001-05-29 2002-12-05 Muratov, Igor Aleksandrovich Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant
WO2003007938A1 (fr) * 2001-07-17 2003-01-30 Aidan, Inc. Procede de traitement de la dermatite atopique
US7214665B2 (en) 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20070232559A1 (en) * 2001-10-01 2007-10-04 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US20030186926A1 (en) * 2001-10-01 2003-10-02 Linden Joel M. 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US8158604B2 (en) 2001-10-01 2012-04-17 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20100152127A1 (en) * 2001-10-01 2010-06-17 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7737127B2 (en) 2001-10-01 2010-06-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20050181028A1 (en) * 2003-01-23 2005-08-18 Foote Mary A. Topical composition and method for treating occlusive wounds
US7989431B2 (en) 2004-08-02 2011-08-02 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
US20090298788A1 (en) * 2004-08-02 2009-12-03 University Of Virginia Patent Foundation And Adenosine Therapeutics, L.L.C. 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US20060040889A1 (en) * 2004-08-02 2006-02-23 Rieger Jayson M 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US20110136755A1 (en) * 2004-08-02 2011-06-09 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US20090253647A1 (en) * 2004-08-02 2009-10-08 University Of Virginia Patent Foundation And Adenosine Therapeutics, L.L.C. 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7605143B2 (en) 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US20060040888A1 (en) * 2004-08-02 2006-02-23 Rieger Jayson M 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity
US20060217343A1 (en) * 2004-08-02 2006-09-28 Rieger Jayson M 2-Polycyclic propynyl adenosine analogs having A2A agonist activity
US7875595B2 (en) 2004-08-02 2011-01-25 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US20090042901A1 (en) * 2005-02-02 2009-02-12 Kowa Co., Ltd. Agent for prevention/therapy of disease caused by keratinocyte growth
FR2884419A1 (fr) * 2005-04-19 2006-10-20 Galderma Sa Composition de type solution filmogene comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
WO2006111426A1 (fr) * 2005-04-19 2006-10-26 Galderma S.A. Composition d'une solution de type filmogene, comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US20080009460A1 (en) * 2006-02-10 2008-01-10 Linden Joel M Method to treat sickle cell disease
US20080064653A1 (en) * 2006-06-19 2008-03-13 University Of Virginia Patent Foundation Use of adenosine a2a modulators to treat spinal cord injury
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20080064669A1 (en) * 2006-08-29 2008-03-13 Rakefet Cohen Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US20090162282A1 (en) * 2007-12-20 2009-06-25 Robert Douglas Thompson Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists
US20110129546A1 (en) * 2008-06-20 2011-06-02 Ignacio Umbert Mill Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same
US20110159077A1 (en) * 2008-09-12 2011-06-30 Patricio Roberto Figueroa Lizama Pentoxifilin-based dermatological pharmaceutical composition, for topical application, in cream, gel, solution, emulsion, liposome and microcapsule form
US10772813B2 (en) 2016-06-03 2020-09-15 Colradel, LLC Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis

Also Published As

Publication number Publication date
EP0544391A1 (fr) 1993-06-02
AU2118792A (en) 1993-03-11
IL99368A (en) 1996-01-19
IL99368A0 (en) 1992-08-18
AU650995B2 (en) 1994-07-07
ZA926248B (en) 1993-03-03
CA2076699A1 (fr) 1993-03-03
JPH06192101A (ja) 1994-07-12

Similar Documents

Publication Publication Date Title
US5565462A (en) Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative
US4743597A (en) Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
EP1028727B1 (fr) Composants ameliorant la penetration dans la peau
AU2006245283B2 (en) Compositions and methods for treating hyperproliferative epidermal diseases
US5723114A (en) Penetration enhancing compositions and methods of their use
KR20090047457A (ko) 6,9-이치환 퓨린 유도체 및 피부 치료를 위한 그의 용도
AU754420B2 (en) Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
JP3508042B2 (ja) セラミド合成促進剤
Faden et al. Effects of BW755C, a mixed cyclo-oxygenase-lipoxygenase inhibitor, following traumatic spinal cord injury in rats
US7528168B2 (en) Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
Touitou et al. Enhanced permeation of theophylline through the skin and its effect on fibroblast proliferation
WO1999026613A1 (fr) Compositions a base d'aminoguanidine destinees au traitement de dermatoses proliferantes
WO1994021271A1 (fr) Procedes et compositions pour induire une separation de phase des deux couches lipidiques de l'epithelium
CA1172168A (fr) Nucleoside de deazapurine, formule et application medicale
LOWE Essential fatty acid deficient hairless mouse: the effects of topical agents on the epidermis
Homo-Delarche et al. In vitro inhibition of prostaglandin production by azathioprine and 6-merchaptopurine
US20090098065A1 (en) Composition and methods for the treatment of skin disorders
Barth et al. Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration
US7431953B2 (en) Skin preparation for external use containing Purpuricenus temminckii frass as the active ingredient
AU2003211175B2 (en) Skin penetration enhancing components
WO2023202989A1 (fr) Traitement de l'alopécie fibrosante frontale
Marks What do you do with a Topical Corticosteroid?
AU2006213973A1 (en) Skin penetration enhancing components
US20060088556A1 (en) Topical formulation and use of buspirone
Verma Percutaneous penetration and anti-inflammatory activity of desfluorotriamcinolone acetonide

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20041015